NEW BRUNSWICK, N.J. / Jul 23, 2024 / Business Wire / Johnson & Johnson (NYSE: JNJ) will participate in the Morgan Stanley 22nd Annual Global Healthcare Conference on Wednesday, September 4th, held at the New York Marriott Marquis, New York, NY. Joaquin Duato, Chairman and Chief Executive Officer and John Reed, Executive Vice President, Innovative Medicine, R&D will represent the Company in a session scheduled at 10:45 am (Eastern Time).
This live audio webcast will be available to investors and other interested parties by accessing the Johnson & Johnson website at www.investor.jnj.com.
The audio webcast replay will be available approximately 48-hrs after the webcast.
| Last Trade: | US$142.27 |
| Daily Change: | -3.96 -2.71 |
| Daily Volume: | 10,576,286 |
| Market Cap: | US$342.870B |
January 08, 2025 December 09, 2024 | |
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE
Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MORE
